The indications and results of the use of teduglutide in patients with short bowel

Curr Opin Clin Nutr Metab Care. 2023 Sep 1;26(5):449-454. doi: 10.1097/MCO.0000000000000964. Epub 2023 Jul 5.

Abstract

Short bowel syndrome (SBS) is a rare condition defined as a reduced residual functional small intestinal length to less than 200 cm often resulting from extensive intestinal resection, and can lead to chronic intestinal failure (CIF). Patients with SBS-CIF are unable to absorb sufficient nutrients or fluids to maintain metabolic homeostasis through oral or enteral intake and require long-term parenteral nutrition and/or fluids and electrolytes. However, complications may arise from both SBS-IF and life-sustaining intravenous support, such as intestinal failure-associated liver disease (IFALD), chronic renal failure, metabolic bone disease and catheter-related complications. An interdisciplinary approach is required to optimize intestinal adaptation and decrease complications. In the last two decades, glucagon-like peptide 2 (GLP-2) analogs have sparked pharmacological interest as a potential disease-modifying therapy for SBS-IF. Teduglutide (TED) is the first developed and marketed GLP-2 analog for SBS-IF. It is approved in the United States, Europe, and Japan for use in adults and children with SBS-IF who are intravenous supplementation dependent. This article discusses the indications, candidacy criteria and results of the use of TED in patients with SBS.

MeSH terms

  • Adult
  • Child
  • Chronic Disease
  • Gastrointestinal Agents / therapeutic use
  • Glucagon-Like Peptide 2 / therapeutic use
  • Humans
  • Intestinal Diseases* / drug therapy
  • Intestinal Failure*
  • Intestine, Small
  • Intestines
  • Short Bowel Syndrome* / drug therapy

Substances

  • teduglutide
  • Gastrointestinal Agents
  • Glucagon-Like Peptide 2